Title:
COMPOSITION FOR ANTICANCER ADJUVANT COMPRISING RIP3 EXPRESSION PROMOTOR AS ACTIVE INGREDIENT, METHOD FOR SCREENING ANTICANCER ADJUVANT WHICH PROMOTES RIP3 EXPRESSION AND ENHANCES SENSITIVITY OF ANTICANCER AGENT, AND METHOD FOR MONITORING SENSITIVITY OF ANTICANCER AGENT
Document Type and Number:
WIPO Patent Application WO/2017/022932
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for an anticancer adjuvant comprising a receptor-interacting protein kinase-3 (RIP3) protein expression promotor or activator as an active ingredient. In addition, the present invention provides a method of promoting cancer cell apoptosis, characterized by co-administering an anticancer agent and a RIP3 protein expression promotor or activator to cancer cells. Also, the present invention relates to a method for screening an anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of an anticancer agent, and a method for monitoring sensitivity of an anticancer agent depending on the RIP3 expression. Accordingly, in the case of a patient lacking the expression of RIP3, it is expected to be an effective treatment strategy to pre-treat a demethylating agent to induce the expression of RIP3 and then to use a conventional chemotherapeutic agent. In addition, in chemotherapy, it is anticipated that the present invention may be an effective strategy in screening an anticancer adjuvant which monitors and enhances sensitivity of an anticancer agent.
Inventors:
KIM YOU-SUN (KR)
KOO GI BANG (KR)
KOO GI BANG (KR)
Application Number:
PCT/KR2016/004777
Publication Date:
February 09, 2017
Filing Date:
May 07, 2016
Export Citation:
Assignee:
AJOU UNIV INDUSTRY-ACADEMIC COOP FOUND (KR)
International Classes:
A61K39/395; A61K31/282; A61K31/506; A61K31/7068; A61K33/243; A61K33/244; C12Q1/68; G01N33/50; G01N33/574
Domestic Patent References:
| WO2008104543A2 | 2008-09-04 |
Foreign References:
| US20100323034A1 | 2010-12-23 | |||
| KR20150094527A | 2015-08-19 |
Other References:
FU, Z. ET AL.: "The Anti-tumor Effect of Shikonin on Osteosarcoma by Inducing RIP1 and RIP3 Dependent Necroptosis", BMC CANCER, vol. 13, no. 580, 6 December 2013 (2013-12-06), pages 1 - 10, XP021169391
HE, J. -X. ET AL.: "Differential Sensitivity of RIP3-proficient and Deficient Murine Fibroblasts to Camptothecin Anticancer Drugs", ACTA PHARMACOL. SIN., vol. 33, no. 3, 2012, pages 426 - 428, XP055216920, [retrieved on 20120123]
KOO, G.-B . ET AL.: "Methylation-dependent Loss of RIP3 Expression in Cancer Represses Programmed Necrosis in Response to Chemotherapeutics", CELL RESEARCH, vol. 25, 2015, pages 707 - 725, XP055362477
MORGAN, M. J. ET AL.: "The Serine Threonine Kinase RIP3: Lost and Found", BMB REP., vol. 48, no. 6, 30 June 2015 (2015-06-30), pages 303 - 312, XP055362482
HE, J. -X. ET AL.: "Differential Sensitivity of RIP3-proficient and Deficient Murine Fibroblasts to Camptothecin Anticancer Drugs", ACTA PHARMACOL. SIN., vol. 33, no. 3, 2012, pages 426 - 428, XP055216920, [retrieved on 20120123]
KOO, G.-B . ET AL.: "Methylation-dependent Loss of RIP3 Expression in Cancer Represses Programmed Necrosis in Response to Chemotherapeutics", CELL RESEARCH, vol. 25, 2015, pages 707 - 725, XP055362477
MORGAN, M. J. ET AL.: "The Serine Threonine Kinase RIP3: Lost and Found", BMB REP., vol. 48, no. 6, 30 June 2015 (2015-06-30), pages 303 - 312, XP055362482
Attorney, Agent or Firm:
AHN, So-Young (KR)
Download PDF: